Prevention of Pulmonary Hypertension by Angiotensin-Converting Enzyme 2 Gene Transfer
- 1 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 54 (2), 365-371
- https://doi.org/10.1161/hypertensionaha.108.125468
Abstract
In spite of recent advancements in the treatment of pulmonary hypertension, successful control has yet to be accomplished. The abundant presence of angiotensin-converting enzyme 2 (ACE2) in the lungs and its impressive effect in the prevention of acute lung injury led us to test the hypothesis that pulmonary overexpression of this enzyme could produce beneficial outcomes against pulmonary hypertension. Monocrotaline (MCT) treatment of mice for 8 weeks resulted in significant increases in right ventricular systolic pressure, right ventricle:left ventricle plus septal weight ratio, and muscularization of pulmonary vessels. Administration of a lentiviral vector containing ACE2, 7 days before MCT treatment prevented the increases in right ventricular systolic pressure (control: 25±1 mm Hg; MCT: 44±5 mm Hg; MCT+ACE2: 26±1 mm Hg; n=6; P P <0.05). A significant attenuation in muscularization of pulmonary vessels induced by MCT was also observed in animals overexpressing ACE2. These beneficial effects were associated with an increase in the angiotensin II type 2 receptor:angiotensin II type 1 receptor mRNA ratio. Also, pulmonary hypertension–induced increases in proinflammatory cytokines were significantly attenuated by lentiviral vector–containing ACE2 treatment. Furthermore, ACE2 gene transfer in mice after 6 weeks of MCT treatment resulted in a significant reversal of right ventricular systolic pressure. These observations demonstrate that ACE2 overexpression prevents and reverses right ventricular systolic pressure and associated pathophysiology in MCT-induced pulmonary hypertension by a mechanism involving a shift from the vasoconstrictive, proliferative, and fibrotic axes to the vasoprotective axis of the renin-angiotensin system and inhibition of proinflammatory cytokines.Keywords
This publication has 40 references indexed in Scilit:
- Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II–Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor DownregulationCirculation Research, 2008
- Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockadeJournal of Human Hypertension, 2006
- Modification of the pulmonary renin–angiotensin system and lung structural remodelling in congestive heart failureClinical Science, 2006
- ACE2: A novel therapeutic target for cardiovascular diseasesProgress in Biophysics and Molecular Biology, 2006
- Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin IIHypertension, 2006
- Role of Type 1 and Type 2 Angiotensin Receptors in Angiotensin II–Induced Cardiomyocyte HypertrophyHypertension, 1996
- Angiotensin-converting enzyme and its clinical significance--a review.Journal of Clinical Pathology, 1983